Steqeyma®

Understanding SteQeyma®

SteQeyma is a prescription medicine used to treat:

• Moderate to severe plaque psoriasis in adults and children 6 years and older who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)
• Active psoriatic arthritis in adults and children 6 years and older
• Moderately to severely active Crohn’s disease in adults
• Moderately to severely active ulcerative colitis in adults

It is not known if SteQema is safe and effective in children less than 6 years of age.

How SteQeyma® Works:

• Binds to the p40 subunit common to IL‑12 and IL‑23, preventing them from interacting with their receptors, which suppresses inflammatory pathways (Th1 and Th17).

• Reduces immune-driven inflammation, improving symptoms in skin, joint, and gastrointestinal conditions.

• Helps decrease joint pain and swelling in psoriatic arthritis, clear skin lesions in plaque psoriasis, and reduce GI inflammation in Crohn’s disease and ulcerative colitis.

FDA Approval:

• December 17, 2024 – Approved by the FDA as a biosimilar to Stelara, with no clinically meaningful differences in safety or efficacy.

• February 2025 – U.S. launch of Steqeyma® following approval.

• June 2025 – FDA approved a new 45 mg/0.5 mL single‑dose vial formulation to provide weight-based dosing for pediatric patients under 60 kg aged 6–17 with plaque psoriasis or psoriatic arthritis.

For more information, please visit the official Steqeyma® patient website. Speak with your healthcare provider to determine if SteQeyma® is the right treatment option for you.